Gastric Cancer Screening by Combined Determination of Serum Helicobacter pylori Antibody and Pepsinogen Concentrations: ABC Method for Gastric Cancer Screening

• Published in: Chinese medical journal 2018-05, Vol.131 (10), p.1232-1239
• Main Authors: Chen, Xian-Zhe, Huang, Cheng-Zhi, Hu, Wei-Xian, Liu, Ying, Yao, Xue-Qing
• Format: Article
• Language: English
• Subjects: Analysis; Antibodies, Bacterial - blood; Antibodies, Bacterial - immunology; Cancer screening; Diagnosis; Endoscopy; Gastric cancer; Gastroscopy; Gastroscopy Surveillance; Helicobacter pylori Antibody; Pepsinogens; Risk Stratification; Stomach Neoplasms; Helicobacter Infections - blood; Helicobacter Infections - immunology; Helicobacter pylori - immunology; Humans; Infections; Mass Screening - methods; Medical prognosis; Medical screening; Methods; Review; Risk factors; Stomach cancer; Stomach Neoplasms - blood; Stomach Neoplasms - microbiology; Surgery
• ISSN: 0366-6999; 2542-5641
• DOI: 10.4103/0366-6999.231512

Objective: Gastroscopy combined with gastric mucosa biopsies is currently regarded as a gold standard for diagnosis of gastric cancer. However, its application is restricted in clinical practice due to its invasive property. A new noninvasive population screening process combining the assay of anti-Helicobacter pylori antibody and serum pepsinogen (PG) (ABC method) is adopted to recognize the high-risk patients for further endoscopy examination, avoiding the unnecessary gastroscopy for most population and saving the cost consumption for mass screening annually. Nevertheless, controversies exist for the grouping of ABC method and the intervals of gastroscopy surveillance for each group. In this review, we summarized these popular concerned topics for providing useful references to the healthcare practitioner in clinical practice. Data Sources: The PubMed databases were systematically searched from the inception dates to November 22, 2017, using the keywords "Helicobacter pylori," "Pepsinogens," and "Stomach Neoplasms." Study Selection: Original articles and reviews on the topics were selected. Results: Anti-H. pylori antibody and serum PG concentration showed significant changes under the different status of H. pylori infection and the progression of atrophic gastritis, which can be used for risk stratification of gastric cancer in clinic. In addition, anti-H. pylori antibody titer can be used for further risk stratification of gastric cancer contributing to determine better endoscopy surveillance interval. Conclusions: The early detection and diagnosis of gastric cancer benefit from the risk stratification, but the cutoff values for H. pylori antibody and serum PG concentration require further modification.